TD Cowen maintains Alignment Healthcare at Buy, lowers price target to $10 from $12

TD Cowen lowered its price target for Alignment Healthcare to $10 from $12, a 16.7% decrease, while maintaining a Buy rating. The new target implies a 37.6% upside from the Oct 30 close of $7.27. Recent analyst price targets for the company range from $8 to $9.

Original reporting
Published Nov 2, 2026, 4:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains Alignment Healthcare at Buy, lowers price target to $10 from $12 — source image
Decision brief

The 30-second read

$ALHCBearishLow
01

Why it matters

A lower target can shift near-term sentiment and options pricing, but without new operational or clinical catalysts it is unlikely to change the fundamental thesis immediately.

02

Market read

Traders may reassess ALHC’s expected valuation path based on the target cut, but the lack of new company-specific data keeps the impact modest.

03

What to watch

Other analysts’ targets (range $8 to $9 over the past month) imply the new $10 target may still be near the upper end of recent Street expectations, reducing incremental impact.

Relevance 4/10Novelty 4/10Timing: today, as the analyst note is published

Background

The piece summarizes TD Cowen’s latest analyst action on Alignment Healthcare, including a reduced price target while keeping the Buy rating.

Company-level read

Ticker impact

$ALHCBearishMedium confidence
Context

TD Cowen maintained Alignment Healthcare at Buy and cut its price target to $10 from $12, implying a lower valuation path for ALHC.

Expected impact

Likely mild downward pressure or capped upside as traders adjust expectations to the lowered target, though the Buy rating may limit downside.

Evidence & confidence

The article is a single-bank price-target cut with no new company fundamentals; such moves typically influence near-term sentiment more than fundamentals.

Market effects

Limited sector signal; this is an idiosyncratic analyst target change rather than a sector-wide catalyst.

No clear regional spillover beyond US small/mid-cap healthcare sentiment.

None indicated.

Counterpoint

The maintained Buy rating suggests the downgrade is more about valuation than deteriorating fundamentals, so the market may treat it as noise.

Key entities

  • Alignment Healthcare

    Subject of the analyst action, with TD Cowen lowering its price target while maintaining a Buy rating.

  • TD Cowen

    Brokerage issuing the maintained Buy and lowered price target.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.